Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects
Pneumonia remains an important cause of morbidity and mortality in older adults with obstructive lung disease. Risk factors for pneumonia, including episodes associated with a hospital admission, have been extensively…
- Trial name
- NCT01763463
- Testing
- New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications, New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
COPD, Chronic Diseases
A Project Ensuring Quality and Cooperation in the Chronic Obstructive Pulmonary Disease (COPD) Treatment
The purpose of this study is to ensure the quality of the COPD treatment in primary care by implementing planned follow-up visits, where the disease condition is evaluated and optimised in accordance with the national COPD…
- Trial name
- KOSMOS (NCT00772733)
- Where
- 11 sites in Denmark
- Volunteers
- 936 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in long term treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Trial name
- NCT02238158
- Testing
- Atrovent® inhalets
- Volunteers
- 595 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease (COPD)
Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)
This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 400/10 mcg twice daily (BID) and MF/F…
- Trial name
- NCT00383435
- Testing
- Mometasone furoate/formoterol (MF/F) combination, Mometasone furoate MDI (MF MDI), Formoterol MDI
- Volunteers
- 1,055 people
- Sponsor
- Organon and Co
Asthma Bronchiale, Bronchiectasis
A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
- Conditions
- Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT06820749
- Testing
- HSK31858
- Where
- China
- Volunteers
- 309 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Pulmonary Disease, Chronic Obstructive
Influence Of Salmeterol Xinafoate/Fluticasone Propionate (50/500 µg BID) On The Course Of The Disease And Exacerbation Frequency In COPD Patients Gold Stage III And IV
This is a 12 month randomized, open-label, parallel-group study to obtain data on the frequency and variability of exacerbations in severe and very severe Chronic Obstructive Pulmonary Disease (COPD) patients (Global Initiative…
- Trial name
- NCT00527826
- Testing
- Salmeterol / Fluticasone (50/500 µg) BID fixed combination, Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers
- Where
- 23 sites in Germany
- Volunteers
- 214 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD
The purpose of the study is to investigate the efficacy and safety of fluticasone furoate/vilanterol Inhalation Powder compared with placebo over a 24 weeks treatment period in subjects of Asian ancestry with Chronic Obstructive…
- Trial name
- NCT01376245
- Testing
- fluticasone furoate/vilanterol
- Where
- 34 sites in China, Philippines and 2 more
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD)
High Intensity Non-Invasive Positive Pressure Ventilation (HINPPV)
The purpose of this pilot study is to evaluate the effect of high intensity non-invasive positive pressure ventilation (HINPPV) for stable, hypercapnic COPD patients.
- Trial name
- HINPPV (NCT01214200)
- Testing
- Bilevel positive airway pressure (BiPAP)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Philips Respironics
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.
- Trial name
- NCT00476099
- Testing
- Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI, Budesonide 200 µg plus formoterol 6 µg DPI, Formoterol 12 µg DPI
- Where
- France
- Volunteers
- 828 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations
Phase 3 study to evaluate the efficacy and safety of a benralizumab in patients with moderate to very severe COPD with a history of frequent COPD exacerbations and elevated peripheral blood eosinophils (≥300/μL).
- Trial name
- RESOLUTE (NCT04053634)
- Testing
- Benralizumab
- Where
- 343 sites in United States, Argentina and 28 more
- Volunteers
- 689 people
- Sponsor
- AstraZeneca
COPD
Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions
This study is an observational multicenter descriptive study. The study will be conducted in primary outpatient medical institutions in different cities of the RF.
- Trial name
- SUPPORT (NCT02248909)
- Where
- 22 sites in Russia
- Volunteers
- 4,232 people
- Sponsor
- AstraZeneca
COPD, Healthy Volunteers
Airvo 3 Respiratory Rate Validation Study
This is a clinical performance testing to validate the accuracy of the Airvo 3 device with respiratory rate algorithm manufactured by Fisher \& Paykel Healthcare for continuous respiratory rate monitoring.
- Trial name
- NCT06329609
- Testing
- Airvo 3 with respiratory rate algorithm
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fisher and Paykel Healthcare
COPD, ILD
Individualized Plan for Improving Adherence to Portable Oxygen Therapy in Patients With Respiratory Pathology
Pilot study with patients with prescription of portable oxygen therapy, to test the impact on adherence of a patient-centered empowerment program, with contents on the nature of the respiratory pathology, the symptom of dyspnea…
- Conditions
- COPD, ILD, Dyspnea
- Trial name
- PIMAOX (NCT04691336)
- Testing
- Educational and Training with counselling
- Where
- Spain
- Volunteers
- 22 people
- Sponsor
- Air Liquide Healthcare Spain
Chronic Obstructive Pulmonary Disease
PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to determine an optimal dose and dosing regimen of PT001 MDI for further evaluation in later stage studies.
- Trial name
- NCT01350128
- Testing
- PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol
- Where
- 8 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection
Study on Home Obstructive Respiratory Exacerbations
Strados Labs has developed the Strados™ Respiratory Care Platform, including the RESP™ Biosensor System, which encompasses a clinically validated wearable, non-invasive, Bluetooth-enabled device capable of remotely collecting…
- Conditions
- COPD Exacerbation, COPD (Chronic Obstructive Pulmonary Disease) With Acute Lower Respiratory Infection, COPD Exacerbation Acute, COPD
- Trial name
- SHORE (NCT06544928)
- Testing
- RESP™ Biosensor
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Strados Labs, Inc.
Pulmonary Disease, Chronic Obstructive
Effect of Aclidinium/Formoterol on Lung Hyperinflation, Exercise Capacity and Physical Activity in Moderate to Severe COPD Patients
The present study is planned to evaluate the effect of the aclidinium bromide/formoterol fumarate 400/12 μg FDC BID on the hyperinflation, exercise endurance and physical activity in patients with moderate to severe COPD.
- Trial name
- ACTIVATE (NCT02424344)
- Testing
- Aclidinium/Formoterol
- Where
- 26 sites in Canada, Germany and 2 more
- Volunteers
- 267 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This is a multicenter, randomized, double-blind, placebo-controlled, 2-period, complete block design cross-over study. The purpose of this study is to evaluate the effect of UMEC/VI 62.5/25 microgram (mcg) on EET as measured by…
- Trial name
- NCT02275052
- Testing
- UMEC/VI DPI, Albuterol/salbutamol MDI
- Where
- 10 sites in United States
- Volunteers
- 198 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation
This retrospective database study will assess differences in the risk of re-hospitalization and other COPD-related exacerbations and costs for patients receiving fluticasone propionate/salmeterol xinafoate combination 250/50…
- Trial name
- NCT01381458
- Testing
- FSC, ACs
- Volunteers
- 1,936 people
- Sponsor
- GlaxoSmithKline
COPD
Therapeutic Effect of PBF-680 in Patients With COPD
The purpose of the study is to investigate the effect of PBF-680 on the chronic inflammation and the lung function of patients with COPD on top of the standard medication.
- Trial name
- Respire (NCT05262218)
- Testing
- PBF-680 10mg
- Where
- 7 sites in Spain
- Volunteers
- 174 people
- Sponsor
- Palobiofarma SL
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.